KeyCorp Has Lowered Expectations for NeuroPace (NASDAQ:NPCE) Stock Price

NeuroPace (NASDAQ:NPCE) had its price objective cut by equities researchers at KeyCorp from $18.00 to $14.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the stock. KeyCorp‘s price objective points to a potential upside of 16.47% from the stock’s previous close.

NPCE has been the topic of several other reports. Weiss Ratings downgraded NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. JPMorgan Chase & Co. lowered NeuroPace from an “overweight” rating to a “neutral” rating and set a $9.00 target price on the stock. in a research report on Friday. Leerink Partners cut NeuroPace from an “outperform” rating to a “market perform” rating and set a $7.00 price target for the company. in a research note on Friday. Cantor Fitzgerald reissued an “overweight” rating on shares of NeuroPace in a report on Tuesday, September 15th. Finally, Guggenheim reissued a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, NeuroPace has a consensus rating of “Moderate Buy” and an average price target of $16.43.

NeuroPace Stock Down 4.0%

Shares of NeuroPace stock opened at $12.02 on Friday. The firm’s 50 day moving average price is $13.35 and its 200-day moving average price is $14.79. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97. NeuroPace has a 52-week low of $11.90 and a 52-week high of $19.60. The company has a market cap of $412.53 million, a P/E ratio of -21.09 and a beta of 1.98.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. The firm had revenue of $22.83 million during the quarter, compared to analyst estimates of $22.61 million. On average, sell-side analysts predict that NeuroPace will post -0.67 EPS for the current fiscal year.

Institutional Trading of NeuroPace

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NPCE. First Light Asset Management LLC lifted its position in NeuroPace by 16.3% during the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after acquiring an additional 401,201 shares during the period. BlackRock Inc. purchased a new stake in NeuroPace during the 2nd quarter valued at about $39,369,000. Deutsche Bank AG acquired a new position in shares of NeuroPace in the second quarter valued at about $14,919,000. Algert Global LLC increased its holdings in shares of NeuroPace by 2.9% in the second quarter. Algert Global LLC now owns 184,774 shares of the company’s stock valued at $2,936,000 after purchasing an additional 5,218 shares during the period. Finally, Lazard Asset Management LLC increased its holdings in shares of NeuroPace by 9.8% in the first quarter. Lazard Asset Management LLC now owns 124,305 shares of the company’s stock valued at $1,635,000 after purchasing an additional 11,078 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace News Roundup

Here’s some of the latest news about NPCE:

• Positive Sentiment: NeuroPace reported a quarterly loss of $0.03 per share, narrower than the $0.11 loss analysts expected and the $0.11 loss a year earlier. Zacks article
• Negative Sentiment: Revenue was $23.1 million, below analysts’ $27.12 million expectation. RNS System revenue was $22.9 million, up just 1.4% year over year, pointing to limited growth. NeuroPace earnings release
• Negative Sentiment: The company lowered its 2026 revenue outlook to $91 million–$92 million, well below the roughly $100.4 million analyst consensus. The guidance reduction, alongside the quarterly revenue miss, is the clearest near-term negative catalyst for NPCE shares. Coverage of NeuroPace’s reduced guidance

About NeuroPace

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.